Application of Radiosensitizers in Cancer Radiotherapy

References

• Krzyszczyk P, Acevedo A, Davidoff EJ, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3–4):79–100. doi:10.1142/S2339547818300020
   PubMed Web of Science ®Google Scholar
• Kułakowski A. The contribution of Marie Skłodowska-Curie to the development of modern oncology. Anal Bioanal Chem. 2011;400(6):1583–1586. doi:10.1007/s00216-011-4712-1
   PubMedGoogle Scholar
• Martin OA, Martin RF. Cancer radiotherapy: understanding the price of tumor eradication. Front Cell Dev Biol. 2020;8:261. doi:10.3389/fcell.2020.00261
   PubMedGoogle Scholar
• Franzone P, Fiorentino A, Barra S, et al. Image-guided radiation therapy (IGRT): practical recommendations of Italian Association of Radiation Oncology (AIRO). Radiol Med. 2016;121(12):958–965. doi:10.1007/s11547-016-0674-x
   PubMed Web of Science ®Google Scholar
• Ge Y, Wu QJ. Knowledge-based planning for intensity-modulated radiation therapy: a review of data-driven approaches. Med Phys. 2019;46(6):2760–2775. doi:10.1002/mp.13526
   PubMed Web of Science ®Google Scholar
• Farhood B, Goradel NH, Mortezaee K, et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin Transl Oncol. 2019;21(3):268–279. doi:10.1007/s12094-018-1934-0
   PubMed Web of Science ®Google Scholar
• Fowler JF, Adams GE, Denekamp J. Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev. 1976;3(4):227–256. doi:10.1016/s0305-7372(76)80012-6
   PubMedGoogle Scholar
• Adams GE. Chemical radiosensitization of hypoxic cells. Br Med Bull. 1973;29(1):48–53. doi:10.1093/oxfordjournals.bmb.a070956
   PubMedGoogle Scholar
• Wen P, Xia J, Cao X, et al. dbCRSR: a manually curated database for regulation of cancer radiosensitivity. Database (Oxford). 2018;2018. doi:10.1093/database/bay049
   Google Scholar
• Garibaldi C, Jereczek-Fossa BA, Marvaso G, et al. Recent advances in radiation oncology. Ecancermedicalscience. 2017;11:785. doi:10.3332/ecancer.2017.785
   PubMed Web of Science ®Google Scholar
• Wang H, Mu X, He H, Zhang XD. Cancer radiosensitizers. Trends Pharmacol Sci. 2018;39(1):24–48. doi:10.1016/j.tips.2017.11.003
   PubMed Web of Science ®Google Scholar
• Hirayama R. Mechanism of oxygen effect for photon andheavy-ion beams. Japanese Journal of Medical Physics. 2014;34(2):65–69.
   Google Scholar
• Oronsky BT, Knox SJ, Scicinski J. Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol. 2011;4(4):189–198. doi:10.1593/tlo.11166
   PubMedGoogle Scholar
• Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7(6):492–508. doi:10.1634/theoncologist.7-6-492
   PubMed Web of Science ®Google Scholar
• Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen homeostasis in the healthy intestine. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol. 2015;309(6):C350–C360. doi:10.1152/ajpcell.00191.2015
   PubMed Web of Science ®Google Scholar
• Richardson RB, Harper ME. Mitochondrial stress controls the radiosensitivity of the oxygen effect: implications for radiotherapy. Oncotarget. 2016;7(16):21469–21483. doi:10.18632/oncotarget.7412
   PubMedGoogle Scholar
• Bel Aiba RS, Dimova EY, Görlach A, Kietzmann T. The role of hypoxia inducible factor-1 in cell metabolism–a possible target in cancer therapy. Expert Opin Ther Targets. 2006;10(4):583–599. doi:10.1517/14728222.10.4.583
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhang S. Hypoxia inducible factor-1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer. J Cell Biochem. 2018;119(9):7707–7718. doi:10.1002/jcb.27120
   PubMed Web of Science ®Google Scholar
• Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metabol. 2014;2(1):19. doi:10.1186/2049-3002-2-19
   PubMedGoogle Scholar
• Boyle RG, Travers S. Hypoxia: targeting the tumour. Anticancer Agents Med Chem. 2006;6(4):281–286. doi:10.2174/187152006777698169
   PubMedGoogle Scholar
• Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol. 2005;16(4–5):523–530. doi:10.1016/j.semcdb.2005.03.001
   PubMed Web of Science ®Google Scholar
• Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. 2019;7:4. doi:10.3389/fcell.2019.00004
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689–721. doi:10.3109/14756366.2014.966704
   PubMed Web of Science ®Google Scholar
• Cabrales P, Intaglietta M. Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids. ASAIO J. 2013;59(4):337–354. doi:10.1097/MAT.0b013e318291fbaa
   PubMed Web of Science ®Google Scholar
• Hardavella G, Karampinis I, Frille A, Sreter K, Rousalova I. Oxygen devices and delivery systems. Breathe (Sheffield, England). 2019;15(3):e108–e116. doi:10.1183/20734735.0204-2019
   PubMedGoogle Scholar
• Choudhury R. Hypoxia and hyperbaric oxygen therapy: a review. Int J Gen Med. 2018;11:431–442. doi:10.2147/ijgm.S172460
   PubMed Web of Science ®Google Scholar
• Stępień K, Ostrowski RP, Matyja E. Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours. Med Oncol (Northwood, London, England). 2016;33(9):101. doi:10.1007/s12032-016-0814-0
   PubMedGoogle Scholar
• Ogawa Y, Kubota K, Ue H, et al. Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas, type II (KORTUC II). Int J Oncol. 2009;34:609–618. doi:10.3892/ijo_00000186
   PubMedGoogle Scholar
• Chapman JD, Webb RG, Borsa J. Radiosensitization of mammalian cells by p-nitroacetophenone. Int J Radiat Biol Relat Stud Phys Chem Med. 1971;19(6):561–573. doi:10.1080/09553007114550741
   PubMed Web of Science ®Google Scholar
• Adams GE, Asquith JC, Dewey DL, Foster JL, Michael BD, Willson RL. Electron affinic sensitization. Int J Radiat Biol Relat Stud Phys Chem Med. 1971;19(6):575–585. doi:10.1080/09553007114550751
   PubMed Web of Science ®Google Scholar
• Higgins GS, O’Cathail SM, Muschel RJ, McKenna WG. Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treat Rev. 2015;41(2):105–113. doi:10.1016/j.ctrv.2014.12.012
   PubMedGoogle Scholar
• Spisz P, Zdrowowicz M, Makurat S, et al. Why does the type of halogen atom matter for the radiosensitizing properties of 5-halogen substituted 4-thio-2’-deoxyuridines? Molecules. 2019;24(15):2819. doi:10.3390/molecules24152819
   PubMedGoogle Scholar
• Brown JM. Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582. Radiat Res. 1975;64(3):633–647. doi:10.2307/3574253
   PubMedGoogle Scholar
• Dische S, Saunders MI, Lee ME, Adams GE, Flockhart IR. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977;35(5):567–579. doi:10.1038/bjc.1977.90
   PubMedGoogle Scholar
• Brown JM. Clinical trials of radiosensitizers: what should we expect? Int J Radiat Oncol Biol Phys. 1984;10(3):425–429. doi:10.1016/0360-3016(84)90063-4
   PubMedGoogle Scholar
• Dische S, Saunders MI, Flockhart IR, Lee ME, Anderson P. Misonidazole-a drug for trial in radiotherapy and oncology. Int J Radiat Oncol Biol Phys. 1979;5(6):851–860. doi:10.1016/0360-3016(79)90070-1
   PubMedGoogle Scholar
• Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–425. doi:10.1038/nrc3958
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Andersen AP, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys. 1989;16(4):1065–1068. doi:10.1016/0360-3016(89)90917-6
   PubMedGoogle Scholar
• Urtasun RC, Chapman JD, Feldstein ML, et al. Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl. 1978;3:271–275.
   PubMedGoogle Scholar
• Wardman P. Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes. Br J Radiol. 2019;92(1093):20170915. doi:10.1259/bjr.20170915
   PubMed Web of Science ®Google Scholar
• Bonnet M, Hong CR, Wong WW, et al. Next-generation hypoxic cell radiosensitizers: nitroimidazole alkylsulfonamides. J Med Chem. 2018;61(3):1241–1254. doi:10.1021/acs.jmedchem.7b01678
   PubMedGoogle Scholar
• Rosenberg A, Knox S. Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys. 2006;64(2):343–354. doi:10.1016/j.ijrobp.2005.10.013
   PubMedGoogle Scholar
• Coleman CN, Wasserman TH, Urtasun RC, et al. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03. Int J Radiat Oncol Biol Phys. 1990;18(2):389–393. doi:10.1016/0360-3016(90)90105-s
   PubMedGoogle Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–447. doi:10.1038/nrc1367
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Radiother Oncol. 1998;46(2):135–146. doi:10.1016/s0167-8140(97)00220-x
   PubMed Web of Science ®Google Scholar
• Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6(10):757–764. doi:10.1016/s1470-2045(05)70292-8
   PubMedGoogle Scholar
• Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncologica (Stockholm, Sweden). 2014;53(5):654–661. doi:10.3109/0284186x.2013.864050
   PubMed Web of Science ®Google Scholar
• Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncologica (Stockholm, Sweden). 2015;54(7):1001–1007. doi:10.3109/0284186x.2014.992547
   PubMed Web of Science ®Google Scholar
• Saksø M, Andersen E, Bentzen J, et al. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncologica (Stockholm, Sweden). 2019;58(10):1495–1501. doi:10.1080/0284186x.2019.1658897
   PubMed Web of Science ®Google Scholar
• Thomson D, Yang H, Baines H, et al. NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol (Royal College of Radiologists (Great Britain)). 2014;26(6):344–347. doi:10.1016/j.clon.2014.03.003
   PubMedGoogle Scholar
• Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2012;102(1):122–129. doi:10.1016/j.radonc.2011.09.010
   PubMed Web of Science ®Google Scholar
• Saksø M, Jensen K, Andersen M, Hansen CR, Eriksen JG, Overgaard J. DAHANCA 28: a phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity. Radiother Oncol. 2020;148:65–72. doi:10.1016/j.radonc.2020.03.025
   PubMedGoogle Scholar
• Oronsky B, Scicinski J, Ning S, et al. RRx-001, a novel dinitroazetidine radiosensitizer. Invest New Drugs. 2016;34(3):371–377. doi:10.1007/s10637-016-0326-y
   PubMedGoogle Scholar
• Oronsky BT, Knox SJ, Scicinski JJ. Is Nitric oxide (NO) the last word in radiosensitization? A review. Transl Oncol. 2012;5(2):66–71. doi:10.1593/tlo.11307
   PubMed Web of Science ®Google Scholar
• Edfeldt NB, Harwood EA, Sigurdsson ST, Hopkins PB, Reid BR. Solution structure of a nitrous acid induced DNA interstrand cross-link. Nucleic Acids Res. 2004;32(9):2785–2794. doi:10.1093/nar/gkh606
   PubMedGoogle Scholar
• Bonavida B, Khineche S, Huerta-Yepez S, Garbán H. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat. 2006;9(3):157–173. doi:10.1016/j.drup.2006.05.003
   PubMedGoogle Scholar
• Nelson EJ, Connolly J, McArthur P. Nitric oxide and s-nitrosylation: excitotoxic and cell signaling mechanism. Biol Cell. 2003;95(1):3–8. doi:10.1016/s0248-4900(03)00004-2
   PubMedGoogle Scholar
• Meffert MK, Premack BA, Schulman H. Nitric oxide stimulates Ca(2+)-independent synaptic vesicle release. Neuron. 1994;12(6):1235–1244. doi:10.1016/0896-6273(94)90440-5
   PubMedGoogle Scholar
• Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216–238. doi:10.1016/j.pharmthera.2009.02.009
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015;14(9):623–641. doi:10.1038/nrd4623
   PubMed Web of Science ®Google Scholar
• Rogers N, Seeger F, Garcin E, Roberts D, Isenberg J. Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow. Review. 2014;5(134). doi:10.3389/fphys.2014.00134
   Google Scholar
• Kondakova IV, Tcheredova VV, Zagrebelnaya GV, Cherdyntseva NV, Kagiya TV, Choinzonov EL. Production of nitric oxide by hypoxic radiosensitizer sanazole. Exp Oncol. 2004;26(4):329–333.
   PubMedGoogle Scholar
• Girard M, Clairmont F, Maneckjee A, Mousseau N, Dawson B, Whitehouse L. 5-Nitroimidazoles. II: unexpected reactivity of ronidazole and dimetridazole with thiols. Can J Chem. 2011;71:1349–1352. doi:10.1139/v93-174
   Google Scholar
• Ng QS, Goh V, Milner J, et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol. 2007;8(2):111–118. doi:10.1016/s1470-2045(07)70001-3
   PubMedGoogle Scholar
• Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology. 2009;74(4):878–883. doi:10.1016/j.urology.2009.03.004
   PubMed Web of Science ®Google Scholar
• Libert N, Tourtier JP, Védrine L, Chargari C, Riou B. Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists. Anesthesiology. 2010;113(3):704–712. doi:10.1097/ALN.0b013e3181ed098d
   PubMedGoogle Scholar
• Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease. Hypertension (Dallas, Tex: 1979). 2018;71:e1–e8. doi:10.1161/hypertensionaha.117.10271
   PubMed Web of Science ®Google Scholar
• Liebmann J, DeLuca AM, Coffin D, et al. In vivo radiation protection by nitric oxide modulation. Cancer Res. 1994;54(13):3365–3368.
   PubMed Web of Science ®Google Scholar
• Schwarz K, Dobiasch S, Nguyen L, Schilling D, Combs SE. Modification of radiosensitivity by curcumin in human pancreatic cancer cell lines. Sci Rep. 2020;10(1):3815. doi:10.1038/s41598-020-60765-1
   PubMedGoogle Scholar
• Verma V. Relationship and interactions of curcumin with radiation therapy. World J Clin Oncol. 2016;7(3):275–283. doi:10.5306/wjco.v7.i3.275
   PubMed Web of Science ®Google Scholar
• Li G, Wang Z, Chong T, Yang J, Li H, Chen H. Curcumin enhances the radiosensitivity of renal cancer cells by suppressing NF-κB signaling pathway. Biomed Pharmacother. 2017;94:974–981. doi:10.1016/j.biopha.2017.07.148
   PubMed Web of Science ®Google Scholar
• da Costa Araldi IC, Bordin FPR, Cadoná FC, et al. The in vitro radiosensitizer potential of resveratrol on MCF-7 breast cancer cells. Chem Biol Interact. 2018;282:85–92. doi:10.1016/j.cbi.2018.01.013
   PubMed Web of Science ®Google Scholar
• Tan Y, Wei X, Zhang W, et al. Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1. Oncol Rep. 2017;37(3):1833–1841. doi:10.3892/or.2017.5413
   PubMedGoogle Scholar
• Mikami S, Ota I, Masui T, et al. Resveratrol‑induced REG III expression enhances chemo‑ and radiosensitivity in head and neck cancer in xenograft mice. Oncol Rep. 2019;42(1):436–442. doi:10.3892/or.2019.7137
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim MS, Lee JW, et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol. 2006;132(2):129–135. doi:10.1007/s00432-005-0052-x
   PubMed Web of Science ®Google Scholar
• Li Y, Sui H, Jiang C, et al. Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway in esophageal cancer cell in vitro and in vivo. Cell Physiol Biochem. 2018;48:2035–2045. doi:10.1159/000492541
   PubMedGoogle Scholar
• Zhang L, Cheng LQ, Zhou Z, Lv LL, Liu GX. Effects of dihydroartemisinin on radiosensitivity of Raji cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2017;33:385–390. doi:10.12047/j.cjap.5565.2017.093
   PubMedGoogle Scholar
• Momtazi-Borojeni AA, Mosafer J, Nikfar B, et al. Curcumin in advancing treatment for gynecological cancers with developed drug- and radiotherapy-associated resistance. Rev Physiol Biochem Pharmacol. 2019;176:107–129. doi:10.1007/112_2018_11
   PubMedGoogle Scholar
• Chen Y, Zhu Z, Zhao W, et al. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol. Radiat Oncol (London, England). 2018;13(1):33. doi:10.1186/s13014-018-0979-0
   PubMedGoogle Scholar
• Ren W, Sha H, Yan J, et al. Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. J Biomater Appl. 2018;33(5):707–724. doi:10.1177/0885328218809019
   PubMedGoogle Scholar
• Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203–208. doi:10.1016/j.ccr.2004.09.003
   PubMed Web of Science ®Google Scholar
• Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004;23(8):1599–1607. doi:10.1038/sj.onc.1207284
   PubMed Web of Science ®Google Scholar
• Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant ewing’s sarcoma cells. Anticancer Res. 2010;30(10):4007–4015.
   PubMed Web of Science ®Google Scholar
• Liao HF, Kuo CD, Yang YC, et al. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res. 2005;46(4):387–393. doi:10.1269/jrr.46.387
   PubMed Web of Science ®Google Scholar
• Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the effectiveness of natural compound mixtures in cancer through Their molecular mode of action. Int J Mol Sci. 2017;18:656. doi:10.3390/ijms18030656
   PubMed Web of Science ®Google Scholar
• Tak JK, Lee JH, Park JW. Resveratrol and piperine enhance radiosensitivity of tumor cells. BMB Rep. 2012;45(4):242–246. doi:10.5483/bmbrep.2012.45.4.242
   PubMed Web of Science ®Google Scholar
• Quan F, Zhao Q, Shao Y, Li H, Zhao R. Resveratrol enhances radiosensitivityof human hypopharyngeal carcinoma cell line in nudemice. Journal of Southern Medical University. 2014;34(11):1646–1649.Chinese.
   Google Scholar
• Shao Y, Quan F, Li HH, Yao XB, Zhao Q, Zhao RM. The radiosensitizing effect of resveratrol on hopypharyngeal carcinoma cell line FADU and its effect on the cell cycle. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35:699–703.
   PubMedGoogle Scholar
• Fang Y, DeMarco VG, Nicholl MB. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci. 2012;103(6):1090–1098. doi:10.1111/j.1349-7006.2012.02272.x
   PubMedGoogle Scholar
• Luo J, Chen X, Chen G, et al. Dihydroartemisinin induces radiosensitivity in cervical cancer cells by modulating cell cycle progression. Saudi Med J. 2013;34(3):254–260.
   PubMedGoogle Scholar
• Zuo ZJ, Wang ST, Jiang LX, et al. Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study. Chin J Integr Med. 2014;34(10):1220–1224.
   Google Scholar
• Zhang ZS, Wang J, Shen YB, et al. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy. Oncol Lett. 2015;10(1):379–383. doi:10.3892/ol.2015.3183
   PubMed Web of Science ®Google Scholar
• Barbuti A, Chen Z-S. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers. 2015;7:2360–2371. doi:10.3390/cancers7040897
   PubMed Web of Science ®Google Scholar
• von Eiff D, Bozorgmehr F, Chung I, et al. Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients. J Thorac Dis. 2020;12(3):782–793. doi:10.21037/jtd.2019.12.74
   PubMedGoogle Scholar
• Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther. 2014;13(2):275–284. doi:10.1158/1535-7163.Mct-13-0791
   PubMedGoogle Scholar
• Xia Y, Li YH, Chen Y, et al. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma. Int J Clin Oncol. 2018;23(3):458–465. doi:10.1007/s10147-018-1240-4
   PubMedGoogle Scholar
• Cowen RL, Williams KJ, Chinje EC, et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res. 2004;64(4):1396–1402. doi:10.1158/0008-5472.can-03-2698
   PubMedGoogle Scholar
• Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol. 2006;1(1):71–79. doi:10.2174/157488406775268192
   PubMedGoogle Scholar
• Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem Pharmacol. 2003;65(11):1807–1815. doi:10.1016/s0006-2952(03)00199-0
   PubMedGoogle Scholar
• Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res. 2004;10(16):5418–5424. doi:10.1158/1078-0432.Ccr-04-0436
   PubMedGoogle Scholar
• Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79–87. doi:10.1200/jco.2005.01.072
   PubMed Web of Science ®Google Scholar
• Rischin D, Peters LJ, O’Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28(18):2989–2995. doi:10.1200/jco.2009.27.4449
   PubMed Web of Science ®Google Scholar
• Wang J, Guise C, Dachs G, et al. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. Biochem Pharmacol. 2014;91(4):436–446. doi:10.1016/j.bcp.2014.08.003
   PubMed Web of Science ®Google Scholar
• Mistry IN, Thomas M, Calder EDD, Conway SJ, Hammond EM. Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(5):1183–1196. doi:10.1016/j.ijrobp.2017.03.024
   PubMed Web of Science ®Google Scholar
• Patterson LH, McKeown SR, Ruparelia K, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer. 2000;82(12):1984–1990. doi:10.1054/bjoc.2000.1163
   PubMed Web of Science ®Google Scholar
• Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. Ann Oncol. 2007;18(6):1098–1103. doi:10.1093/annonc/mdm120
   PubMedGoogle Scholar
• Albertella MR, Loadman PM, Jones PH, et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res. 2008;14(4):1096–1104. doi:10.1158/1078-0432.Ccr-07-4020
   PubMed Web of Science ®Google Scholar
• Hong CR, Dickson BD, Jaiswal JK, et al. Cellular pharmacology of evofosfamide (TH-302): a critical re-evaluation of its bystander effects. Biochem Pharmacol. 2018;156:265–280. doi:10.1016/j.bcp.2018.08.027
   PubMed Web of Science ®Google Scholar
• Takakusagi Y, Kishimoto S, Naz S, et al. Radiotherapy synergizes with the hypoxia-activated prodrug evofosfamide: in vitro and in vivo studies. Antioxid Redox Signal. 2018;28:131–140. doi:10.1089/ars.2017.7106
   PubMedGoogle Scholar
• Peeters SG, Zegers CM, Biemans R, et al. TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin Cancer Res. 2015;21:2984–2992. doi:10.1158/1078-0432.Ccr-15-0018
   PubMed Web of Science ®Google Scholar
• Lohse I, Rasowski J, Cao P, et al. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. Oncotarget. 2016;7(23):33571–33580. doi:10.18632/oncotarget.9654
   PubMedGoogle Scholar
• Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35:S224–s243. doi:10.1016/j.semcancer.2015.01.001
   PubMed Web of Science ®Google Scholar
• Larue RT, Van De Voorde L, Berbée M, et al. A Phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer. 2016;16:644. doi:10.1186/s12885-016-2709-z
   PubMed Web of Science ®Google Scholar
• Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL, Laskin JD. Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity. Mol Cancer Ther. 2010;9(6):1852–1863. doi:10.1158/1535-7163.Mct-09-1098
   PubMedGoogle Scholar
• Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res. 1988;116(1):100–113. doi:10.2307/3577481
   PubMedGoogle Scholar
• Haffty BG, Wilson LD, Son YH, et al. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys. 2005;61(1):119–128. doi:10.1016/j.ijrobp.2004.07.730
   PubMedGoogle Scholar
• Burd R, Lavorgna SN, Lenaz L, et al. Radiosensitization of hypoxic tumors by the bioreductive agent apaziquone (EO9, EOquin (TM)). Clin Cancer Res. 2005;9008S–9008S.
   Google Scholar
• Wang Z, Ding Y, Geng G, Zhu N. Analysis of energy efficiency retrofit schemes for heating, ventilating and air-conditioning systems in existing office buildings based on the modified bin method. Energy Convers Manage. 2014;77:233–242. doi:10.1016/j.enconman.2013.09.037
   Web of Science ®Google Scholar
• Suwala AK, Kahlert UD, Maciaczyk J. Abstract 2515: pharmacological WNT-inhibition acts synergistically with chemo- and radiotherapy by overcoming treatment-resistance in glioma stem cells. Cancer Res. 2016;76(14Supplement):2515. doi:10.1158/1538-7445
   Google Scholar
• Saker J, Huang S, Park L, Pedersen M, Kragh M, Harari P. Abstract 1027: EGFR targeting antibody SYM004 causes radiosensitization in tumor cells expressing wild-type K-Ras via modulation of MAPK signaling. Cancer Res. 2013;73(8Supplement):1027. doi:10.1158/1538-7445
   Google Scholar
• Prabakaran PJ, Javaid AM, Swick AD, et al. Radiosensitization of adenoid cystic carcinoma with MDM2 inhibition. Clin Cancer Res. 2017;23(20):6044–6053. doi:10.1158/1078-0432.Ccr-17-0969
   PubMedGoogle Scholar
• Zhuang HM, Miao XL, Zhao ZQ, Zhang L. Application of nano calcium phosphate biomaterials and bone tissue engineering on in exercise-induced injury. Adv Mater Res. 2014;951:109–112. doi:10.4028/www.scientific.net/AMR.951.109
   Google Scholar
• Liu WL, Gao M, Tzen KY, et al. Targeting phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget. 2014;5(11):3662–3672. doi:10.18632/oncotarget.1978
   PubMedGoogle Scholar
• Chen Y-H, Wei M-F, Wang C-W, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357(2):582–590. doi:10.1016/j.canlet.2014.12.015
   PubMed Web of Science ®Google Scholar
• Jayakumar S, Patwardhan RS, Pal D, Sharma D, Sandur SK. Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: possible involvement of ROS and thioredoxin reductase. Biochem Biophys Res Commun. 2016;478(1):446–454. doi:10.1016/j.bbrc.2016.06.144
   PubMed Web of Science ®Google Scholar
• Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol. 1987;13(5):733–739. doi:10.1016/0360-3016(87)90292-6
   PubMedGoogle Scholar
• Wang S, Zhao P, Zhang C, Bu Y. Mechanisms responsible for high energy radiation induced damage to single-stranded DNA modified by radiosensitizing 5-halogenated deoxyuridines. J Phys Chem B. 2016;120:2649–2657. doi:10.1021/acs.jpcb.5b11432
   PubMedGoogle Scholar
• Benej M, Hong X, Vibhute S, et al. Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci. 2018;115(42):10756–10761. doi:10.1073/pnas.1808945115
   PubMed Web of Science ®Google Scholar
• Lhuillier C, Rudqvist N-P, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 2019;11(1):40. doi:10.1186/s13073-019-0653-7
   PubMed Web of Science ®Google Scholar
• Bourillon L, Bourgier C, Gaborit N, et al. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer. 2019;145(7):1838–1851. doi:10.1002/ijc.32273
   PubMed Web of Science ®Google Scholar
• González JE, Barquinero JF, Lee M, García O, Casaco A. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther. 2012;13(2):71–76. doi:10.4161/cbt.13.2.18439
   PubMed Web of Science ®Google Scholar
• Buchanan IM, Scott T, Tandle AT, et al. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med. 2011;15(9):1999–2006. doi:10.1111/j.1582-4934.2010.01122.x
   PubMedGoogle Scholar
• Nieder C, Mannsåker B, Dalhaug A, Pawinski A, Haukland E. Palliative radiotherapy in cancer patients with increased serum c-reactive protein level. Article. In Vivo (Brooklyn). 2016;30(5):581–586.
   Google Scholar
• Kanegasaki S, Matsushima K, Shiraishi K, Nakagawa K, Tsuchiya T. Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy. Cancer Res. 2014;74:5070–5078. doi:10.1158/0008-5472
   PubMedGoogle Scholar
• Krüger M, Amort J, Wilgenbus P, et al. The anti-apoptotic PON2 protein is Wnt-catenin-regulated and correlates with radiotherapy resistance in OSCC patients. Oncotarget. 2016;7(32).
   Google Scholar
• Cao Y, Yang L, Jiang W, et al. Therapeutic evaluation of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme for treating of nasopharyngeal carcinomas. Mol Ther. 2014;22(2):371–377. doi:10.1038/mt.2013.257
   PubMedGoogle Scholar
• Walker JM, Rolig AS, Charych DH, et al. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. Immunother Cancer. 2020;8(1). doi:10.1136/jitc-2019-000464
   Google Scholar
• Gandellini P, Rancati T, Valdagni R, Zaffaroni N. miRNAs in tumor radiation response: bystanders or participants? Trends Mol Med. 2014;20(9):529–539. doi:10.1016/j.molmed.2014.07.004
   PubMedGoogle Scholar
• de Jong MC, Ten Hoeve JJ, Grénman R, et al. Pretreatment microRNA expression impacting on epithelial-to-mesenchymal transition predicts intrinsic radiosensitivity in head and neck cancer cell lines and patients. Clin Cancer Res. 2015;21:5630–5638. doi:10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Huang A, Ono Y. Estimation of wrist flexion angle from muscle thickness changes measured by a flexible ultrasonic sensor. IEEE. 2016;188–191.
   Google Scholar
• Shao Y, Song X, Jiang W, et al. MicroRNA-621 acts as a tumor radiosensitizer by directly targeting SETDB1 in hepatocellular carcinoma. Mol Ther. 2019;27(2):355–364. doi:10.1016/j.ymthe.2018.11.005
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang L, Rodriguez-Aguayo C, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014;5:5671. doi:10.1038/ncomms6671
   PubMed Web of Science ®Google Scholar
• Song L, Peng L, Hua S, et al. miR-144-5p enhances the radiosensitivity of non-small-cell lung cancer cells via targeting ATF2. Biomed Res Int. 2018;2018:5109497. doi:10.1155/2018/5109497
   PubMed Web of Science ®Google Scholar
• Luo J, Si ZZ, Li T, et al. MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-induced activation of the DNA repair pathway. Am J Physiol Cell Physiol. 2019;316(3):C299–c311. doi:10.1152/ajpcell.00189.2018
   PubMedGoogle Scholar
• Wu SJ, Chen J, Wu B, Wang YJ, Guo KY. MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma. J Exp Clin Cancer Res. 2018;37(1):18. doi:10.1186/s13046-017-0639-5
   PubMedGoogle Scholar
• Yin H, Ma J, Chen L, et al. MiR-99a enhances the radiation sensitivity of non-small cell lung cancer by targeting mTOR. Cell Physiol Biochem. 2018;46(2):471–481. doi:10.1159/000488615
   PubMedGoogle Scholar
• Pajic M, Froio D, Daly S, et al. miR-139-5p Modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Res. 2018;78(2):501–515. doi:10.1158/0008-5472.Can-16-3105
   PubMed Web of Science ®Google Scholar
• Hu Z, Tie Y, Lv G, Zhu J, Fu H, Zheng X. Transcriptional activation of miR-320a by ATF2, ELK1 and YY1 induces cancer cell apoptosis under ionizing radiation conditions. Int J Oncol. 2018;53(4):1691–1702. doi:10.3892/ijo.2018.4497
   PubMedGoogle Scholar
• Song Y, Zuo Y, Qian XL, et al. Inhibition of microRNA-21-5p promotes the radiation sensitivity of non-small cell lung cancer through HMSH2. Cell Physiol Biochem. 2017;43(3):1258–1272. doi:10.1159/000481839
   PubMedGoogle Scholar
• Zhang L, Wang C, Xue Z-X. Inhibition of miR-630 enhances the cell resistance to radiation by directly targeting CDC14A in human glioma. Am J Transl Res. 2017;9(3):1255–1265.
   PubMedGoogle Scholar
• Gu J, Li Y, Zeng J, et al. Knockdown of HIF-1α by siRNA-expressing plasmid delivered by attenuated Salmonella enhances the antitumor effects of cisplatin on prostate cancer. Sci Rep. 2017;7(1):7546. doi:10.1038/s41598-017-07973-4
   PubMedGoogle Scholar
• Mehta M, Basalingappa K, Griffith JN, et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016;7(40):64820–64835. doi:10.18632/oncotarget.11706
   PubMedGoogle Scholar
• Qi R, Qiao T, Zhuang X. Small interfering RNA targeting S100A4 sensitizes non-small-cell lung cancer cells (A549) to radiation treatment. Onco Targets Ther. 2016;9:3753–3762. doi:10.2147/ott.S106557
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Scuric Z, Schiestl RH, Okamoto N, Takahashi A, Ohnishi T. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat Res. 2006;166(3):454–462. doi:10.1667/rr3606.1
   PubMedGoogle Scholar
• Khan Z, Khan AA, Prasad GBKS, Khan N, Tiwari RP, Bisen PS. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus. Radiother Oncol. 2016;118(2):359–368. doi:10.1016/j.radonc.2015.12.007
   PubMed Web of Science ®Google Scholar
• Jackson MR, Bavelaar BM, Waghorn PA, et al. Radiolabeled oligonucleotides targeting the RNA subunit of telomerase inhibit telomerase and induce DNA damage in telomerase-positive cancer cells. Cancer Res. 2019;79(18):4627–4637. doi:10.1158/0008-5472
   PubMedGoogle Scholar
• Cao F, Ju X, Chen D, et al. Phosphorothioate‑modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy. Mol Med Rep. 2017;16(2):2089–2094. doi:10.3892/mmr.2017.6778
   PubMedGoogle Scholar
• Park SI, Park SJ, Lee J, et al. Inhibition of cyclic AMP response element-directed transcription by decoy oligonucleotides enhances tumor-specific radiosensitivity. Biochem Biophys Res Commun. 2016;469(3):363–369. doi:10.1016/j.bbrc.2015.11.122
   PubMedGoogle Scholar
• Yu C, Yu Y, Xu Z, et al. Antisense oligonucleotides targeting human telomerase mRNA increases the radiosensitivity of nasopharyngeal carcinoma cells. Mol Med Rep. 2015;11(4):2825–2830. doi:10.3892/mmr.2014.3105
   PubMedGoogle Scholar
• Hernández-Rivera M, Kumar I, Cho SY, et al. High-performance hybrid bismuth–carbon nanotube based contrast agent for X-ray CT imaging. ACS Appl Mater Interfaces. 2017;9:5709–5716. doi:10.1021/acsami.6b12768
   PubMedGoogle Scholar
• Haume K, Rosa S, Grellet S, et al. Gold nanoparticles for cancer radiotherapy: a review. Cancer Nanotechnol. 2016;7(1):8. doi:10.1186/s12645-016-0021-x
   PubMedGoogle Scholar
• Ma N, Liu P, He N, Gu N, Wu F-G, Chen Z. Action of gold nanospikes-based nanoradiosensitizers: cellular internalization, radiotherapy, and autophagy. ACS Appl Mater Interfaces. 2017;9:31526–31542. doi:10.1021/acsami.7b09599
   PubMedGoogle Scholar
• Li Y, Yun K-H, Lee H, Goh S-H, Suh Y-G, Choi Y. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. Biomaterials. 2019;197:12–19. doi:10.1016/j.biomaterials.2019.01.004
   PubMed Web of Science ®Google Scholar
• Yang X, Yang M, Pang B, Vara M, Xia Y. Gold nanomaterials at work in biomedicine. Chem Rev. 2015;115(19):10410–10488. doi:10.1021/acs.chemrev.5b00193
   PubMed Web of Science ®Google Scholar
• Cui L, Her S, Borst GR, Bristow RG, Jaffray DA, Allen C. Radiosensitization by gold nanoparticles: will they ever make it to the clinic? Radiother Oncol. 2017;124(3):344–356. doi:10.1016/j.radonc.2017.07.007
   PubMed Web of Science ®Google Scholar
• Zhang XD, Luo Z, Chen J, et al. Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance. Sci Rep. 2015;5:8669. doi:10.1038/srep08669
   PubMed Web of Science ®Google Scholar
• Luo D, Wang X, Zeng S, Ramamurthy G, Burda C, Basilion JP. Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles? Chem Sci. 2019;10(35):8119–8128. doi:10.1039/c9sc02290b
   PubMed Web of Science ®Google Scholar
• Mathur P, Jha S, Ramteke S, Jain NK. Pharmaceutical aspects of silver nanoparticles. Artif Cells, Nanomed Biotechnol. 2018;46(sup1):115–126. doi:10.1080/21691401.2017.1414825
   PubMed Web of Science ®Google Scholar
• Li S, Porcel E, Remita H, et al. Platinum nanoparticles: an exquisite tool to overcome radioresistance. Cancer Nanotechnol. 2017;8(1):4. doi:10.1186/s12645-017-0028-y
   PubMed Web of Science ®Google Scholar
• Pinel S, Thomas N, Boura C, Barberi-Heyob M. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment. Adv Drug Deliv Rev. 2019;138:344–357. doi:10.1016/j.addr.2018.10.013
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu P, Ma J, et al. Enhancement of radiosensitization by silver nanoparticles functionalized with polyethylene glycol and aptamer as1411 for glioma irradiation therapy. Int J Nanomedicine. 2019;14:9483–9496. doi:10.2147/IJN.S224160
   PubMed Web of Science ®Google Scholar
• Liu Z, Tan H, Zhang X, et al. Enhancement of radiotherapy efficacy by silver nanoparticles in hypoxic glioma cells. Artif Cells, Nanomed Biotechnol. 2018;46(sup3):S922–s930. doi:10.1080/21691401.2018.1518912
   PubMed Web of Science ®Google Scholar
• Fathy MM. Biosynthesis of silver nanoparticles using thymoquinone and evaluation of their radio-sensitizing activity. BioNanoScience. 2020;10(1):260–266. doi:10.1007/s12668-019-00702-3
   Google Scholar
• Rajaee A, Wang S, Zhao L, et al. Multifunction bismuth gadolinium oxide nanoparticles as radiosensitizer in radiation therapy and imaging. Phys Med Biol. 2019;64(19):195007. doi:10.1088/1361-6560/ab2154
   PubMedGoogle Scholar
• Fält T, Söderberg M, Wassélius J, Leander P. Material decomposition in dual-energy computed tomography separates high-Z elements from iodine, identifying potential contrast media tailored for dual contrast medium examinations. J Comput Assist Tomogr. 2015;39(6):975–980. doi:10.1097/rct.0000000000000298
   PubMedGoogle Scholar
• Chen X, Song J, Chen X, Yang H. X-ray-activated nanosystems for theranostic applications. Chem Soc Rev. 2019;48(11):3073–3101. doi:10.1039/c8cs00921j
   PubMedGoogle Scholar
• Liu Y, Zhang P, Li F, et al. Metal-based nano enhancers for future radiotherapy: radiosensitizing and synergistic effects on tumor cells. Theranostics. 2018;8(7):1824–1849. doi:10.7150/thno.22172
   PubMed Web of Science ®Google Scholar
• Mardare AI, Mardare CC, Kollender JP, Huber S, Hassel AW. Basic properties mapping of anodic oxides in the hafnium-niobium-tantalum ternary system. Sci Technol Adv Mater. 2018;19(1):554–568. doi:10.1080/14686996.2018.1498703
   PubMed Web of Science ®Google Scholar
• Taupin F, Flaender M, Delorme R, et al. Gadolinium nanoparticles and contrast agent as radiation sensitizers. Phys Med Biol. 2015;60(11):4449–4464. doi:10.1088/0031-9155/60/11/4449
   PubMed Web of Science ®Google Scholar
• Shahbazi M-A, Faghfouri L, Ferreira MPA, et al. The versatile biomedical applications of bismuth-based nanoparticles and composites: therapeutic, diagnostic, biosensing, and regenerative properties. Chem Soc Rev. 2020;49(4):1253–1321. doi:10.1039/C9CS00283A
   PubMed Web of Science ®Google Scholar
• Le Duc G, Roux S, Paruta-Tuarez A, et al. Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnol. 2014;5(1):4. doi:10.1186/s12645-014-0004-8
   PubMedGoogle Scholar
• Hu P, Fu Z, Liu G, et al. Gadolinium-based nanoparticles for theranostic MRI-guided radiosensitization in hepatocellular carcinoma. Front Bioeng Biotechnol. 2019;7:368. doi:10.3389/fbioe.2019.00368
   PubMedGoogle Scholar
• Detappe A, Lux F, Tillement O. Pushing radiation therapy limitations with theranostic nanoparticles. Nanomedicine (London, England). 2016;11(9):997–999. doi:10.2217/nnm.16.38
   PubMedGoogle Scholar
• McGinnity TL, Dominguez O, Curtis TE, Nallathamby PD, Hoffman AJ, Roeder RK. Hafnia (HfO2) nanoparticles as an X-ray contrast agent and mid-infrared biosensor. Nanoscale. 2016;8(28):13627–13637. doi:10.1039/C6NR03217F
   PubMedGoogle Scholar
• Jayaraman V, Bhavesh G, Chinnathambi S, Ganesan S, Aruna P. Synthesis and characterization of hafnium oxide nanoparticles for bio-safety. Mater Express. 2014. doi:10.1166/mex.2014.1190
   Google Scholar
• Bonvalot S, Le Pechoux C, De Baere T, et al. First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. Clin Cancer Res. 2016;23:908–917. doi:10.1158/1078-0432
   PubMedGoogle Scholar
• Prasad K, Bazaka O, Chua M, et al. Metallic biomaterials: current challenges and opportunities. Materials (Basel). 2017;10(8):884. doi:10.3390/ma10080884
   PubMed Web of Science ®Google Scholar
• Jin Y, Ma X, Zhang S, et al. A tantalum oxide-based core/shell nanoparticle for triple-modality image-guided chemo-thermal synergetic therapy of esophageal carcinoma. Cancer Lett. 2017;397:61–71. doi:10.1016/j.canlet.2017.03.030
   PubMed Web of Science ®Google Scholar
• Rathnayake S, Mongan J, Torres AS, et al. In vivo comparison of tantalum, tungsten, and bismuth enteric contrast agents to complement intravenous iodine for double-contrast dual-energy CT of the bowel. Contrast Media Mol Imaging. 2016;11(4):254–261. doi:10.1002/cmmi.1687
   PubMedGoogle Scholar
• Lu Y-C, Yang C-X, Yan X-P. Radiopaque tantalum oxide coated persistent luminescent nanoparticles as multimodal probes for in vivo near-infrared luminescence and computed tomography bioimaging. Nanoscale. 2015;7(42):17929–17937. doi:10.1039/C5NR05623C
   PubMedGoogle Scholar
• Brown R, Tehei M, Oktaria S, et al. High-Z nanostructured ceramics in radiotherapy: first evidence of ta2O5-induced dose enhancement on radioresistant cancer cells in an MV photon field. Part Part Syst Charact. 2014;31(4):500–505. doi:10.1002/ppsc.201300276
   Google Scholar
• Song G, Chao Y, Chen Y, et al. All-in-one theranostic nanoplatform based on hollow TaOx for chelator-free labeling imaging, drug delivery, and synergistically enhanced radiotherapy. Adv Funct Mater. 2016;26(45):8243–8254. doi:10.1002/adfm.201603845
   Web of Science ®Google Scholar
• Song G, Chen Y, Liang C, et al. Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy. Adv Mater. 2016;28(33):7143–7148. doi:10.1002/adma.201602111
   PubMed Web of Science ®Google Scholar
• Bulatov A, Moskvin L, Rodinkov O, Ermakov S. Department of analytical chemistry of saint petersburg state university celebrates one hundred and fifty years anniversary: international year of the periodic table of chemical elements. Talanta. 2020;206:119759. doi:10.1016/j.talanta.2019.03.081
   PubMedGoogle Scholar
• Chellan P, Sadler PJ. The elements of life and medicines. Philos Trans a Math Phys Eng Sci. 2015;373(2037). doi:10.1098/rsta.2014.0182
   PubMedGoogle Scholar
• Hossain M, Su M. Nanoparticle location and material-dependent dose enhancement in X-ray radiation therapy. J Phys Chem C. 2012;116(43):23047–23052. doi:10.1021/jp306543q
   PubMed Web of Science ®Google Scholar
• Yu X, Li A, Zhao C, Yang K, Chen X, Li W. Ultrasmall semimetal nanoparticles of bismuth for dual-modal computed tomography/photoacoustic imaging and synergistic thermoradiotherapy. ACS Nano. 2017;11(4):3990–4001. doi:10.1021/acsnano.7b00476
   PubMed Web of Science ®Google Scholar
• Qiu J, Xiao Q, Zheng X, et al. Single W18O49 nanowires: a multifunctional nanoplatform for computed tomography imaging and photothermal/photodynamic/radiation synergistic cancer therapy. Nano Res. 2015;8(11):3580–3590. doi:10.1007/s12274-015-0858-z
   Web of Science ®Google Scholar
• Gong L, Yan L, Zhou R, Xie J, Wu W, Gu Z. Two-dimensional transition metal dichalcogenide nanomaterials for combination cancer therapy. J Mater Chem B. 2017;5(10):1873–1895. doi:10.1039/C7TB00195A
   PubMed Web of Science ®Google Scholar
• Cheng X, Yong Y, Dai Y, et al. Enhanced radiotherapy using bismuth sulfide nanoagents combined with photo-thermal treatment. Theranostics. 2017;7(17):4087–4098. doi:10.7150/thno.20548
   PubMed Web of Science ®Google Scholar
• Feng L, Yang D, Gai S, et al. Single bismuth tungstate nanosheets for simultaneous chemo-, photothermal, and photodynamic therapies mediated by near-infrared light. Chem Eng J. 2018;351:1147–1158. doi:10.1016/j.cej.2018.06.170
   Web of Science ®Google Scholar
• Detappe A, Thomas E, Tibbitt MW, et al. Ultrasmall silica-based bismuth gadolinium nanoparticles for dual magnetic resonance–computed tomography image guided radiation therapy. Nano Lett. 2017;17(3):1733–1740. doi:10.1021/acs.nanolett.6b05055
   PubMedGoogle Scholar
• Yong Y, Zhou L, Zhang S, et al. Gadolinium polytungstate nanoclusters: a new theranostic with ultrasmall size and versatile properties for dual-modal MR/CT imaging and photothermal therapy/radiotherapy of cancer. NPG Asia Mater. 2016;8(5):e273–e273. doi:10.1038/am.2016.63
   Google Scholar
• Ma P, Xiao H, Yu C, et al. Enhanced cisplatin chemotherapy by iron oxide nanocarrier-mediated generation of highly toxic reactive oxygen species. Nano Lett. 2017;17(2):928–937. doi:10.1021/acs.nanolett.6b04269
   PubMed Web of Science ®Google Scholar
• Vallabani NVS, Singh S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics. 3 Biotech. 2018;8(6):279. doi:10.1007/s13205-018-1286-z
   PubMedGoogle Scholar
• Tang GD, Li ZZ, Ma L, et al. Three models of magnetic ordering in typical magnetic materials. Phys Rep. 2018;758:1–56. doi:10.1016/j.physrep.2018.06.009
   Google Scholar
• Nica V, Caro C, Páez-Muñoz JM, Leal MP, Garcia-Martin ML. Bi-magnetic core-shell CoFe(2)O(4)@MnFe(2)O(4) nanoparticles for in vivo theranostics. Nanomaterials (Basel, Switzerland). 2020;10(5). doi:10.3390/nano10050907
   PubMedGoogle Scholar
• Meidanchi A, Akhavan O, Khoei S, Shokri A, Hajikarimi Z, Khansari N. ZnFe2O4 nanoparticles as radiosensitizers in radiotherapy of human prostate cancer cells. Mater Sci Eng C Mater Biol Appl. 2015;46:394–399. doi:10.1016/j.msec.2014.10.062
   PubMed Web of Science ®Google Scholar
• Hidayatullah M, Nurhasanah I, Budi WS. ZnFe2O4nanoparticles for potential application in radiosensitization. J Phys Conf Ser. 2016;694:012028. doi:10.1088/1742-6596/694/1/012028
   Google Scholar
• Salunkhe A, Khot V, Patil SI, et al. Magneto-chemotherapy with high-magnetic-moment iron oxide nanoparticles for cancer theranostics. ACS Appl Bio Mater. 2020;3(4):2305–2313. doi:10.1021/acsabm.0c00077
   PubMedGoogle Scholar
• Shao L, Gao Y, Yan F. Semiconductor quantum dots for biomedicial applications. Sensors (Basel). 2011;11(12):11736–11751. doi:10.3390/s111211736
   PubMed Web of Science ®Google Scholar
• Juzenas P, Chen W, Sun Y-P, et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev. 2008;60(15):1600–1614. doi:10.1016/j.addr.2008.08.004
   PubMed Web of Science ®Google Scholar
• Cline B, Delahunty I, Xie J. Nanoparticles to mediate X-ray-induced photodynamic therapy and Cherenkov radiation photodynamic therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(2):e1541. doi:10.1002/wnan.1541
   PubMedGoogle Scholar
• Yang W, Read PW, Mi J, et al. Semiconductor nanoparticles as energy mediators for photosensitizer-enhanced radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(3):633–635. doi:10.1016/j.ijrobp.2008.06.1916
   PubMedGoogle Scholar
• Nakayama M, Sasaki R, Ogino C, et al. Titanium peroxide nanoparticles enhanced cytotoxic effects of X-ray irradiation against pancreatic cancer model through reactive oxygen species generation in vitro and in vivo. Radiat Oncol. 2016;11(1):91. doi:10.1186/s13014-016-0666-y
   PubMedGoogle Scholar
• Morita K, Miyazaki S, Numako C, et al. Characterization of titanium dioxide nanoparticles modified with polyacrylic acid and H2O2 for use as a novel radiosensitizer. Free Radic Res. 2016;50(12):1319–1328. doi:10.1080/10715762.2016.1241879
   PubMed Web of Science ®Google Scholar
• Jin J, Zhao Q. Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. J Nanobiotechnology. 2020;18(1):75. doi:10.1186/s12951-020-00629-y
   PubMed Web of Science ®Google Scholar
• Sun H, Wang X, Zhai S. The rational design and biological mechanisms of nanoradiosensitizers. Nanomaterials (Basel, Switzerland). 2020;10(3):504. doi:10.3390/nano10030504
   PubMedGoogle Scholar
• Martel A. Recent progress in biomedical applications of nanodiamonds. Nanosci Nanotechnol. 2018;8:11–24. doi:10.5923/j.nn.20180801.03
   Google Scholar
• Jia Y, Weng Z, Wang C, et al. Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes. Oncol Lett. 2017;13(1):206–214. doi:10.3892/ol.2016.5402
   PubMedGoogle Scholar
• Chan L, He L, Zhou B, et al. Cancer-targeted selenium nanoparticles sensitize cancer cells to continuous γ radiation to achieve synergetic chemo-radiotherapy. Chem Asian J. 2017;12(23):3053–3060. doi:10.1002/asia.201701227
   PubMedGoogle Scholar
• Bromma K, Cicon L, Beckham W, Chithrani DB. Gold nanoparticle mediated radiation response among key cell components of the tumour microenvironment for the advancement of cancer nanotechnology. Sci Rep. 2020;10(1):12096. doi:10.1038/s41598-020-68994-0
   PubMedGoogle Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi:10.1186/s12951-018-0392-8
   PubMed Web of Science ®Google Scholar
• Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):20. doi:10.1186/s40824-019-0166-x
   PubMedGoogle Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951. doi:10.1038/nbt.3330
   PubMed Web of Science ®Google Scholar